The August 2009 private placement resulted in gross proceeds to Raptor of approximately $2.4 million or $2.3 million after placement agent fees and other expenses. The warrant exchange raised approximately $2.6 million in net proceeds for Raptor.
Raptor intends to use the net proceeds to fund programs for its late-stage drug product candidates and to execute its corporate strategy, including closing the proposed merger with TorreyPines Therapeutics, which is expected to close in the fourth quarter of 2009.
The August 2009 Private Placement consisted of the sale of an aggregate 7.46 million units, with each unit priced at $0.32. Each unit consists of one share of the company's common stock and a two-year warrant to purchase one-half of one share of the company's common stock.
The units sold represent an aggregate of 7.46 million shares of the company's common stock and warrants to purchase up to 3.73 million shares of the company's common stock. The warrants are exercisable for up to two years from the date of issuance at $0.60 per share and $0.75 per share during the first and second years following issuance, respectively.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index